#1 Clinical Trials Search in Europe

Single Guide Rna Containing A Sequence Complementary To Human Alb Locus Gene, Intron 1, Target Region

This article explores groundbreaking clinical trials using an innovative drug called “Single Guide RNA Containing A Sequence Complementary To Human ALB Locus Gene, Intron 1, Target Region” in combination with CRISPR gene editing technology. These trials aim to treat genetic disorders such as hemophilia B and alpha-1 antitrypsin deficiency (AATD)-associated lung disease. The studies focus on evaluating the safety, effectiveness, and potential of this cutting-edge approach to address previously challenging genetic conditions.

Table of Contents

What is Single Guide RNA?

Single guide RNA (sgRNA) is a key component of an innovative gene therapy approach that holds promise for treating genetic disorders. It is part of a technology called CRISPR-Cas9, which allows scientists to make precise changes to DNA[1]. In the context of the treatments we’re discussing, the sgRNA is specifically designed to target a particular region of a gene involved in either hemophilia B or alpha-1 antitrypsin deficiency.

How Does It Work?

The single guide RNA works in conjunction with another component called Cas9, which is an enzyme that can cut DNA. The sgRNA acts like a GPS, guiding the Cas9 enzyme to a specific location in the DNA. Once there, Cas9 makes a cut, allowing scientists to insert, delete, or modify genes[1]. This process is known as gene editing.

Potential Applications

This technology is being explored for various genetic disorders. Two notable applications currently in clinical trials are for hemophilia B and alpha-1 antitrypsin deficiency-associated lung disease.

Hemophilia B Treatment

Hemophilia B is a genetic disorder that affects blood clotting. People with this condition lack a protein called Factor IX (FIX), which is crucial for blood clotting[1]. The gene therapy being studied, called REGV131-LNP1265, aims to insert a functional copy of the FIX gene into liver cells.

This treatment uses a single guide RNA that is complementary to a specific region of the albumin gene in liver cells. The therapy is designed to insert the FIX gene at this location, allowing the liver to produce the missing clotting factor[1].

Alpha-1 Antitrypsin Deficiency Treatment

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that can lead to lung and liver disease. People with AATD don’t produce enough of a protein called alpha-1 antitrypsin, which protects the lungs from damage[2].

The treatment being studied, called NTLA-3001, uses a similar approach to the hemophilia B therapy. It aims to insert a functional copy of the SERPINA1 gene (which produces alpha-1 antitrypsin) into liver cells, allowing them to produce the missing protein[2].

Clinical Trials

Both treatments are currently being evaluated in clinical trials:

  • The hemophilia B treatment (REGV131-LNP1265) is being studied in a Phase 1/2 trial for adults with severe or moderately severe hemophilia B[1].
  • The AATD treatment (NTLA-3001) is also in a Phase 1/2 trial for adults with AATD-associated lung disease[2].

These trials aim to assess the safety, tolerability, and effectiveness of these gene therapies.

Safety Considerations

As with any new treatment, safety is a primary concern. The clinical trials are carefully designed to monitor for any potential side effects. Some key safety considerations include:

  • Immune responses to the treatment components
  • Potential off-target effects (unintended changes to DNA)
  • Long-term safety of gene editing

Participants in these trials will be closely monitored for any adverse events[1][2].

Future Prospects

If successful, these gene therapies could potentially offer long-lasting treatments for hemophilia B and AATD. Instead of regular infusions or injections, patients might receive a one-time treatment that allows their body to produce the missing proteins.

However, it’s important to note that these treatments are still in the early stages of research. More studies will be needed to fully understand their effectiveness and long-term safety before they can become widely available[1][2].

Aspect Hemophilia B Trial AATD-Associated Lung Disease Trial
Drug Name REGV131-LNP1265 NTLA-3001
Target Condition Hemophilia B Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease
Main Objective Evaluate safety, tolerability, and Factor IX activity Evaluate safety and tolerability
Key Eligibility Males ≥18 years with severe/moderately severe hemophilia B Adults 18-75 years with AATD-associated lung disease
Primary Endpoints Adverse events, Factor IX activity, bleeding rate Treatment-emergent adverse events
Study Duration Up to 104 weeks Not specified, but includes long-term follow-up

FAQ

  • What is the purpose of these clinical trials? These clinical trials aim to evaluate the safety, tolerability, and effectiveness of a new gene editing therapy using CRISPR technology. The trials focus on treating genetic disorders such as hemophilia B and alpha-1 antitrypsin deficiency (AATD)-associated lung disease.
  • How does the drug work? The drug contains a single guide RNA that targets a specific region of the human albumin gene. When combined with CRISPR-Cas9 technology, it allows for precise gene editing to potentially correct or modify the genetic cause of the disease.
  • Who can participate in these trials? Eligibility varies by trial, but generally includes adult patients with confirmed diagnoses of the targeted genetic disorders. For example, the hemophilia B trial includes males with severe or moderately severe hemophilia B, while the AATD trial includes adults with AATD-associated lung disease.
  • What are the main outcomes being measured? The trials primarily measure safety through monitoring adverse events. They also assess the therapy's effectiveness by measuring changes in relevant biomarkers, such as clotting factor IX activity for hemophilia B or alpha-1 antitrypsin protein levels for AATD.
  • How long do these trials last? The duration of follow-up varies, but participants are typically monitored for extended periods, often up to 104 weeks (2 years) or longer, to assess long-term safety and efficacy of the treatment.

Ongoing Clinical Trials on Single Guide Rna Containing A Sequence Complementary To Human Alb Locus Gene, Intron 1, Target Region

  • Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Safety of NTLA-3001 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung Disease

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland

Glossary

  • CRISPR: CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows for precise modifications to DNA sequences.
  • Single Guide RNA: A short RNA sequence that guides the CRISPR-Cas9 enzyme to a specific location in the genome for targeted gene editing.
  • Hemophilia B: A genetic bleeding disorder caused by a deficiency in clotting factor IX, leading to impaired blood clotting.
  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic disorder that can lead to lung and liver disease due to low levels or abnormal function of the alpha-1 antitrypsin protein.
  • Gene Insertion Therapy: A treatment approach that involves adding a functional gene into a person's cells to correct a genetic disorder.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Adeno-Associated Virus (AAV): A small virus used as a vector to deliver genetic material into cells for gene therapy purposes.
  • Lipid Nanoparticle (LNP): Tiny particles made of lipids (fats) used to encapsulate and deliver genetic material or drugs into cells.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body, which can be important for assessing the safety of new treatments.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-regv131-and-lnp1265-for-adults-with-hemophilia-b/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-of-ntla-3001-for-adults-with-alpha-1-antitrypsin-deficiency-related-lung-disease/